News|Videos|November 20, 2023
HER2-Positive Endometrial Cancer: A Targeted Approach to Treatment
Author(s)Ritu Salani, MD, Bhavana Pothuri, MD
The role of HER2 status and targeted therapy with trastuzumab in advanced endometrial cancer, emphasizing the need for effective management of cardiac toxicities and comorbidities.
Advertisement
Episodes in this series
Advertisement
Related to this article
First-line pembrolizumab monotherapy met the primary end point of PFS in dMMR advanced/recurrent endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
Dr Akhade on Building the Evidence Base for Low-Dose Immunotherapy
3
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
4
Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
5